In the original article, there was a mistake in [Table 1](#T1){ref-type="table"} as published. The heading "**miR-BARTs**" has been removed and the heading "**BART miRNA cluster 1&2**" has been replaced with "**Others**." In addition, reference 22 has been added to rows 3 and 10 under "**Others**." The corrected [Table 1](#T1){ref-type="table"} appears below.

###### 

EBV miRNAs targeting host immune related genes.

  **miRNA**                   **Host targeting genes**   **Target**                       **References**   **EBV infected cells**
  --------------------------- -------------------------- -------------------------------- ---------------- ------------------------
  **BART miRNAs cluster 1**                                                                                
  miR-BART1-3p                IL12B                      Adaptive immunity                \(22\)           LCL
  miR-BART1-5p                LY75                       Adaptive immunity                \(23\)           LCL
  miR-BART1-5p, 3p            IFI30                      Adaptive immunity                \(24\)           LCL
  miR-BART15-3p               NLRP3                      Innate immunity                  \(25\)           BL
  miR-BART16-5p               CREBBP                     Innate immunity                  \(26\)           BL, EBVaGC
  miR-BART17-5p               TAP2                       Adaptive immunity                \(24\)           LCL
  miR-BART6-3p                RIG-I                      Innate immunity                  \(27\)           NPC
  **BART miRNAs cluster 2**                                                                                
  miR-BART18-5p               MAP3K2                     BCR signals, Adaptive Immunity   \(28\)           BL
  miR-BART8-5p, 3p            STAT1                      Innate immunity                  \(29\)           NKTL
  miR-BART22-3p               IL12B                      Adaptive immunity                \(22\)           LCL
  miR-BART10-3p               IL12B                      Adaptive immunity                \(22\)           LCL
  miR-BART20-5p               IFNG                       Innate immunity                  \(29\)           NKTL
  **Others**                                                                                               
  miR BARTs                   NF-kB signal               Innate immunity                  \(30\)           NPC
  miR-BART2-5p                MICB                       Immunoreaction against NK cell   \(31\)           LCL
  miR-BART2-5p                IL12B                      Adaptive immunity                (22, 32)         LCL
  miR-BART2-5p                CSTB                       Adaptive immunity                \(24\)           LCL
  miR-BART2-5p                LGMN                       Adaptive immunity                \(24\)           LCL
  miR-BHRF1                   IL-1R1                     Innate immunity                  \(33\)           LCL
  miR-BHRF1-2-5p              MALT1                      BCR signals, Adaptive Immunity   \(34\)           LCL, DLBL
  miR-BHRF1-2-5p              GRB2                       BCR signals, Adaptive Immunity   \(34\)           LCL, DLBL
  miR-BHRF1-2-5p              PAG1                       BCR signals, Adaptive Immunity   \(34\)           LCL, DLBL
  miR-BHRF1-2-3p              IL12B                      Adaptive immunity                (22, 32)         LCL
  miR-BHRF1-2-3p              CSTB                       Adaptive immunity                \(24\)           LCL
  miR-BHRF1-2-3p              TAP2                       Adaptive immunity                \(24\)           LCL
  miR-BHRF1-3-5p              CXCL-11                    Innate immunity                  \(35\)           BL, DLBCL

*LCL, Lymphoblastoid cell lines; BL, Burkitt lymphoma; NPC, Nasopharengeal carcinoma; EBVaGC, EBV asspciated gastridc carcinoma; NKTL, NK/T lymphoma; DLBCL, Diffuce large B cell lymphoma*.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
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